Recbio Technology has picked European CRO OCT Clinical to run a phase 3 trial of the Chinese biotech's COVID-19 vaccine.
The study will evaluate the vaccine in healthy patients aged 18 and upward who have not previously been vaccinated for COVID-19 and have not been infected with the virus in the past six months. Recbio is targeting as many as 10,000 volunteers but has only asked OCT to enroll 2,000 participants across 11 research sites.
OCT will be in charge of regulatory and logistics support, project management, volunteer recruitment and monitoring for the trial. The financial terms of the deal weren’t disclosed.
Read the full article at Fierce official website. [1]
